Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Breaks Above 200-Day Moving Average – Should You Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s stock price crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $6.15 and traded as high as $7.30. Cumberland Pharmaceuticals shares last traded at $6.70, with a volume of 90,046 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, Cumberland Pharmaceuticals presently has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Trading Up 2.6%

The firm has a market cap of $122.39 million, a P/E ratio of -11.51 and a beta of 0.06. The stock has a 50 day simple moving average of $7.37 and a 200-day simple moving average of $6.19.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07). The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 34.40% and a negative return on equity of 28.81%.

Institutional Trading of Cumberland Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Cumberland Pharmaceuticals in the second quarter worth about $412,000. Bank of New York Mellon Corp bought a new stake in Cumberland Pharmaceuticals during the second quarter worth approximately $379,000. Dimensional Fund Advisors LP increased its stake in Cumberland Pharmaceuticals by 1.5% during the first quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company’s stock worth $898,000 after acquiring an additional 4,081 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Cumberland Pharmaceuticals during the first quarter valued at approximately $66,000. 15.51% of the stock is currently owned by hedge funds and other institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company headquartered in Nashville, Tennessee. Founded in 1999, the company develops, acquires, and commercializes branded prescription products, with an emphasis on hospital acute care, gastroenterology, and other specialty areas.

Its portfolio has included Caldolor, an intravenous formulation of ibuprofen used for pain and fever; Vaprisol, an injectable treatment for certain cases of hyponatremia; Kristalose, a prescription form of lactulose used to treat constipation; and Omeclamox-Pak, a therapy for Helicobacter pylori infection and associated ulcer disease.